A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors

What Was Tested

This randomized controlled trial paper looks at Octreotide and Somatostatin.

Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs).

Lanreotide is more expensive and given by deep subcutaneous injection, whereas octLAR is given intramuscularly.

The researchers evaluated patient preference between these agents in terms of injection site pain.

Who Took Part

Patients with NETs received injections every 4 weeks.

Secondary end points included patient-reported preference.

How the Study Was Run

The design is described as randomized and single-blind.

Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.

In this single-blind Octreotide study one party knew the assignments and the other did not.

Arm 1: octLAR × 3, then lanreotide × 3; arm 2: reverse order.

Self-reported injection site pain scores (range, 0-10) were obtained after each of the first three injections.

Primary end point was comparison of mean pain scores over the first three injections.

What Was Measured

PubMed files the paper under topics including Neuroendocrine Tumors, Octreotide, Pain, Patient Outcome Assessment, Peptides, Cyclic and Somatostatin.

What This Means in Plain Language

The paper is a randomized and single-blind study of Octreotide and Somatostatin.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (JCO oncology practice), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page.